VERTEX PHARMACEUTICALS INC / MA Cost of Goods Sold (Deprecated 2018-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Cost of Goods Sold (Deprecated 2018-01-31) of $104.38 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-07-26.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-07-26
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $104.38M, a 46.59% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $71.61M, a 52.41% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $83.71M, a 40.35% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $72.19M, a 35.63% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $272.68M, a 31.85% increase from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $206.81M, a 76.53% increase from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $117.15M, a 194.90% increase from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $39.73M, a 55.35% decline from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|
| 2018-06-30 | $104.38M 10-Q · filed 2018-07-26 | $176.00M 10-Q · filed 2018-07-26 | $259.71M derived: sum of 3 quarters · filed 2018-07-26 | $331.89M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2018-03-31 | $71.61M 10-Q · filed 2018-04-27 | $155.32M derived: sum of 2 quarters · filed 2018-04-27 | $227.51M derived: sum of 3 quarters · filed 2018-04-27 | $298.72M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2017-12-31 | $83.71M 10-K · filed 2018-02-15 | $155.90M derived: sum of 2 quarters · filed 2018-02-15 | $227.10M derived: sum of 3 quarters · filed 2018-07-26 | $272.68M 10-K · filed 2018-02-15 | ||
| 2017-09-30 | $72.19M 10-K · filed 2018-02-15 | $143.39M derived: sum of 2 quarters · filed 2018-07-26 | $188.96M 10-Q · filed 2017-10-30 | $250.03M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2017-06-30 | $71.20M 10-Q · filed 2018-07-26 | $70.53M 10-Q · filed 2017-07-28 | $118.19M 10-Q · filed 2018-07-26 | $116.78M 10-Q · filed 2017-07-28 | $177.84M derived: sum of 3 quarters · filed 2018-07-26 | $231.06M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $46.99M 10-Q · filed 2018-04-27 | $46.24M 10-Q · filed 2017-04-28 | $106.63M derived: sum of 2 quarters · filed 2018-04-27 | $159.86M derived: sum of 3 quarters · filed 2018-04-27 | $204.01M derived: sum of 4 quarters · filed 2018-04-27 | |
| 2016-12-31 | $59.65M 10-K · filed 2018-02-15 | $112.87M derived: sum of 2 quarters · filed 2018-02-15 | $157.02M derived: sum of 3 quarters · filed 2018-02-15 | $206.81M 10-K · filed 2018-02-15 | ||
| 2016-09-30 | $53.22M 10-K · filed 2018-02-15 | $97.38M derived: sum of 2 quarters · filed 2018-02-15 | $147.16M 10-Q · filed 2017-10-30 | $209.26M derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2016-06-30 | $44.15M 10-K · filed 2018-02-15 | $93.94M 10-Q · filed 2017-07-28 | $156.03M derived: sum of 3 quarters · filed 2018-02-15 | $186.30M derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2016-03-31 | $49.79M 10-K · filed 2018-02-15 | $111.88M derived: sum of 2 quarters · filed 2018-02-15 | $142.15M derived: sum of 3 quarters · filed 2018-02-15 | $157.56M derived: sum of 4 quarters · filed 2018-02-15 | ||
| 2015-12-31 | $62.09M 10-K · filed 2017-02-23 | $92.36M derived: sum of 2 quarters · filed 2017-02-23 | $107.77M derived: sum of 3 quarters · filed 2017-02-23 | $117.15M 10-K · filed 2018-02-15 | ||
| 2015-09-30 | $30.27M 10-K · filed 2017-02-23 | $45.68M derived: sum of 2 quarters · filed 2017-02-23 | $55.06M 10-Q · filed 2016-10-31 | $66.35M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-06-30 | $15.41M 10-K · filed 2017-02-23 | $24.79M 10-Q · filed 2016-08-01 | $36.08M derived: sum of 3 quarters · filed 2017-02-23 | $46.29M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-03-31 | $9.38M 10-K · filed 2017-02-23 | $20.67M derived: sum of 2 quarters · filed 2017-02-23 | $30.88M derived: sum of 3 quarters · filed 2017-02-23 | $40.53M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2014-12-31 | $11.29M 10-K · filed 2016-02-16 | $21.50M derived: sum of 2 quarters · filed 2016-02-16 | $31.15M derived: sum of 3 quarters · filed 2016-02-16 | $39.73M 10-K · filed 2017-02-23 | ||
| 2014-09-30 | $10.21M 10-K · filed 2016-02-16 | $19.86M derived: sum of 2 quarters · filed 2016-02-16 | $28.43M 10-Q · filed 2015-10-30 | $41.72M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-06-30 | $9.65M 10-K · filed 2016-02-16 | $18.23M 10-Q · filed 2015-08-04 | $31.51M derived: sum of 3 quarters · filed 2016-02-16 | $51.56M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-03-31 | $8.57M 10-K · filed 2016-02-16 | $21.85M derived: sum of 2 quarters · filed 2016-02-16 | $41.90M derived: sum of 3 quarters · filed 2016-02-16 | $66.60M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2013-12-31 | $13.28M 10-K · filed 2015-02-13 | $33.33M derived: sum of 2 quarters · filed 2015-02-13 | $58.02M derived: sum of 3 quarters · filed 2015-02-13 | $88.98M 10-K · filed 2016-02-16 | ||
| 2013-09-30 | $20.05M 10-K · filed 2015-02-13 | $44.74M derived: sum of 2 quarters · filed 2015-02-13 | $75.70M 10-Q · filed 2014-11-06 | $151.29M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-06-30 | $24.70M 10-K · filed 2015-02-13 | $55.65M 10-Q · filed 2014-07-31 | $131.25M derived: sum of 3 quarters · filed 2015-02-13 | $161.93M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-03-31 | $30.95M 10-K · filed 2015-02-13 | $106.55M derived: sum of 2 quarters · filed 2015-02-13 | $137.23M derived: sum of 3 quarters · filed 2015-02-13 | $241.78M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2012-12-31 | $75.59M 10-K · filed 2014-02-11 | $106.28M derived: sum of 2 quarters · filed 2014-02-11 | $210.82M derived: sum of 3 quarters · filed 2014-02-11 | $236.74M 10-K · filed 2015-02-13 | ||
| 2012-09-30 | $30.68M 10-K · filed 2014-02-11 | $135.23M derived: sum of 2 quarters · filed 2014-02-11 | $161.15M 10-Q · filed 2013-11-07 | $184.08M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-06-30 | $104.55M 10-K · filed 2014-02-11 | $130.47M 10-Q · filed 2013-08-02 | $153.40M derived: sum of 3 quarters · filed 2014-02-11 | $188.69M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-03-31 | $25.92M 10-K · filed 2014-02-11 | $48.85M derived: sum of 2 quarters · filed 2014-02-11 | $84.14M derived: sum of 3 quarters · filed 2014-02-11 | $89.54M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2011-12-31 | $22.94M 10-K · filed 2013-03-01 | $58.22M derived: sum of 2 quarters · filed 2013-03-01 | $63.63M derived: sum of 3 quarters · filed 2013-03-01 | $63.63M 10-K · filed 2014-02-11 | ||
| 2011-09-30 | $35.28M 10-K · filed 2013-03-01 | $40.69M derived: sum of 2 quarters · filed 2013-03-01 | $40.69M 10-Q · filed 2012-11-06 | |||
| 2011-06-30 | $5.40M 10-K · filed 2013-03-01 | $5.40M 10-Q · filed 2012-08-08 | ||||
| 2011-03-31 | $0.00 10-K · filed 2013-03-01 | |||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 | |||||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | $0.00 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |